Point-of-Care Molecular Testing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 3.4 billion
Estimated Base Value
2035 Forecast
US$ 7.0 billion
Projected Market Value
CAGR 2026–2035
7.5%
Compound Annual Growth
Largest Segment
Infectious Disease Molecular Tests
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
bioMérieux
Emerging Players
Visby Medical, Cue Health
Point-of-Care Molecular Testing Market Overview
The Point-of-Care Molecular Testing Market encompasses diagnostic systems and reagents designed for nucleic acid amplification and detection at or near the patient. These systems provide rapid, accurate results outside centralized laboratories, improving turnaround times for clinical decision-making. The market serves hospitals, clinics, physician offices, urgent care centers, and retail clinics, enabling immediate patient management across various decentralized healthcare settings. Key applications include infectious disease detection, genetic testing, and companion diagnostics, leveraging portable and automated platforms with integrated digital solutions for data management and connectivity.
The Point-of-Care Molecular Testing Market is estimated at $3.4 Bn in 2025 and is forecast to reach $7.0 Bn in 2035, growing at a CAGR of 7.5% (2025-2035). Demand is driven by the need for faster diagnostic results for timely treatment decisions, the increasing global prevalence of infectious diseases, and expanding healthcare access in remote areas. However, high initial costs of devices and reagents, stringent regulatory pathways, and challenges in maintaining accuracy in diverse settings restrain market growth.
The market is segmented by Type (Infectious Disease, Oncology, Genetic Disorder), Product (POC Molecular Analyzers, Test Cartridges & Kits), Technology (Polymerase Chain Reaction Based, Isothermal Nucleic Acid Amplification Based), End-User (Hospitals & Clinics, Physician Offices), Form (Benchtop, Portable, Handheld Devices), and Functionality (Qualitative Analysis, Quantitative Analysis). Geographically, the market is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include bioMérieux, QuidelOrtho, QIAGEN, and DiaSorin. The full report provides detailed analysis of these segments, regional dynamics, and competitive landscape.
Market Definition & Overview
The Point-of-Care Molecular Testing Market comprises the development, manufacturing, and commercialization of diagnostic systems and reagents that perform nucleic acid amplification and detection directly at or near the patient. These digital molecular diagnostics deliver rapid, accurate results outside of traditional centralized laboratories, significantly improving turnaround times and accessibility for clinical decision-making. This market leverages advanced portable and automated platforms, often with integrated digital solutions for data management and connectivity. Key applications span infectious disease detection, genetic testing, and companion diagnostics, enabling immediate patient management in various decentralized healthcare settings.
Scope
- Global market analysis across all major regions including North America, Europe, Asia Pacific, Latin America, and MEA.
- Focus on clinical diagnostic applications within hospitals, clinics, physician offices, and retail pharmacies.
- Market sizing and forecasting from historical data (e.g., 2022) through a future projection period (e.g., 2032).
- Coverage of infectious disease, oncology, and genetic testing segments.
Inclusions
- Portable and handheld molecular diagnostic instruments and analyzers.
- PCR, isothermal amplification, and microarray-based POC molecular systems.
- Single-use cartridges, test kits, and proprietary reagents for molecular assays.
- Integrated software solutions for data interpretation, connectivity, and electronic health record integration.
- Molecular tests for infectious diseases including COVID-19, influenza, RSV, and STIs.
- Point-of-care molecular tests for oncology, pharmacogenomics, and genetic predispositions.
Exclusions
- Traditional centralized laboratory-based molecular diagnostic systems and high-throughput sequencers.
- Non-molecular point-of-care tests, such as rapid antigen tests or immunoassay-based diagnostics.
- Research-use-only (RUO) molecular testing products and academic research equipment.
- Medical imaging diagnostics and unrelated medical device categories like surgical instruments.
- Services exclusively for test sample collection and transportation without molecular analysis.
Market Size Forecast
Executive Summary
• The Point-of-Care Molecular Testing market is valued at $3.4 Bn in 2025 and is forecast to reach $7.0 Bn by 2035, reflecting a robust CAGR of 7.5% as demand accelerates across every major segment and region over the ten-year outlook.
• Infectious Disease Molecular Tests leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying competitive pressures are spurring strategic M&A and vertical integration, favoring diversified diagnostics providers capable of end-to-end solutions and robust global distribution networks.
• Decentralized healthcare models, coupled with ongoing pandemic preparedness initiatives, are accelerating the adoption of rapid, accurate POC molecular diagnostics across diverse clinical settings globally.
• Advancements in multiplexing and microfluidics are enhancing test accuracy and throughput, while evolving regulatory frameworks aim to streamline market access for innovative POC molecular platforms.
• Emerging markets present significant untapped opportunities for infectious disease POC solutions, contrasting with developed regions where oncology and pharmacogenomics represent next-wave strategic expansion areas.
• Strategic investments are prioritizing R&D for next-generation platforms and bolstering resilient supply chains, crucial for ensuring consistent access and mitigating geopolitical risks in diagnostics delivery.
• The market is poised for deep integration into precision medicine and value-based care, driven by AI-enabled analytics and interconnected digital health ecosystems for proactive patient management.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The Point-of-Care Molecular Testing Market was valued at $3.4 billion in the base year, reflecting its significant current footprint in medical diagnostics.
Future Market Expansion
This market is projected to expand robustly, reaching $7.0 billion by the forecast year, driven by increasing demand for rapid and accessible diagnostics.
Robust Growth Outlook
Exhibiting a strong Compound Annual Growth Rate (CAGR) of 7.5%, the market demonstrates a sustained upward trajectory, indicating healthy investment and adoption.
Infectious Disease Dominance
Infectious disease testing is anticipated to remain a leading segment within the market, driven by the critical need for rapid and accurate pathogen identification at the point of care.
Regional Market Leadership
North America is expected to maintain its leadership position in the market, attributed to advanced healthcare infrastructure and significant R&D investments.
Decentralization Trend
A notable trend in this market is the increasing demand for decentralized testing platforms, enabling faster diagnostic results closer to the patient and improving clinical decision-making.
Market Dynamics
Market Trends
- Rapid, decentralized testing platforms are gaining significant traction.
- AI and digital health integration is enhancing diagnostic capabilities.
- Multiplexed assays for comprehensive pathogen detection are becoming common.
- Demand for user-friendly, cartridge-based systems is rising steadily.
Growth Drivers
- Faster diagnostic results are crucial for timely treatment decisions.
- Increasing global prevalence of infectious diseases fuels demand.
- Expanding healthcare access in remote areas drives adoption.
- Government funding and initiatives promote early disease detection.
Restraints
- High initial cost of testing devices and reagents limits widespread adoption.
- Stringent regulatory pathways pose significant hurdles for market entry.
- Maintaining accuracy and reliability at diverse point-of-care settings is challenging.
- Inadequate reimbursement policies impede market growth and investment.
Opportunities
- Developing new platforms for non-infectious disease targets like cancer.
- Significant growth potential in expanding markets, especially emerging economies.
- Creating accessible home-based or self-testing molecular diagnostic solutions.
- Strategic partnerships integrating POC diagnostics into broader healthcare.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Infectious Disease Molecular TestsOncology Molecular TestsGenetic Disorder Molecular TestsPharmacogenomic Molecular TestsBlood Screening Molecular TestsCardiovascular Health Molecular TestsNeurological Health Molecular TestsWomen's Health Molecular Tests |
| Product | POC Molecular AnalyzersTest Cartridges & KitsReagents & ConsumablesSoftware SolutionsIntegrated PlatformsServices & Support |
| Technology | Polymerase Chain Reaction BasedIsothermal Nucleic Acid Amplification BasedNext Generation Sequencing BasedMicrofluidics BasedCRISPR Based DiagnosticsLateral Flow Assay BasedBiosensor Based |
| End-User | Hospitals & ClinicsPhysician OfficesDiagnostic & Reference LaboratoriesUrgent Care CentersRetail Clinics & PharmaciesHome Care SettingsAmbulatory Surgical Centers |
| Form | Benchtop DevicesPortable DevicesHandheld Devices |
| Functionality | Qualitative AnalysisQuantitative AnalysisMultiplex TestingAutomated Sample to ResultConnectivity & Data IntegrationRapid Result CapabilitiesOn-Demand Testing |
Regional Analysis
- North America dominates the PoC molecular testing market, driven by its advanced healthcare infrastructure, substantial R&D investments, and rapid adoption of innovative diagnostics. High prevalence of infectious diseases and strong government support further solidify its leading position.
- Asia-Pacific emerges as the fastest-growing region for PoC molecular testing, attributed to improving healthcare infrastructure, rising disposable incomes, and increasing awareness about early disease diagnosis. A large patient pool and government initiatives supporting diagnostic access also fuel this rapid expansion.
- Europe shows a noteworthy trend towards decentralized PoC molecular testing, aiming for enhanced diagnostic accessibility and faster results outside traditional labs. This push is supported by favorable regulatory landscapes and initiatives to integrate these advanced platforms into primary care settings for improved patient outcomes.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- North America holds a significant share, driven by a well-established healthcare infrastructure, high adoption of advanced molecular technologies, and strong R&D investments.
- Favorable reimbursement policies and a high demand for rapid, accurate diagnostics contribute to its stable growth.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Latin America experiences strong growth fueled by increasing healthcare expenditure, expanding access to medical services, and a rising burden of infectious diseases.
- Efforts to improve diagnostic capabilities in remote and underserved areas are key drivers for POC molecular testing adoption.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Europe represents a mature market characterized by sophisticated healthcare systems, a strong focus on decentralized testing, and increasing government funding for point-of-care solutions.
- Stringent regulatory frameworks and a push for improved patient outcomes support steady market development.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region dominates due to its vast population, increasing healthcare access, and rising prevalence of infectious diseases, driving significant investment in POC diagnostics.
- Robust economic growth and government initiatives further propel market expansion across key countries like China and India.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region shows emerging potential with varying growth rates, driven by healthcare infrastructure development in wealthier nations and growing awareness of rapid diagnostics for infectious diseases.
- Investments in improving diagnostic accessibility across the region are gradually increasing.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | As the largest market with a highly advanced healthcare system and significant R&D investment, the US is a major adopter of POC molecular testing. Strong demand for rapid diagnostics and digital health integration drives its market leadership. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As the largest economy in South America with a significant burden of infectious diseases, Brazil presents a substantial market for POC molecular testing. Increasing public and private healthcare investments are boosting demand for accessible diagnostics. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany's highly advanced healthcare system and strong economy drive the adoption of cutting-edge medical technologies, including digital molecular POC. Extensive R&D and a focus on quality diagnostics maintain its prominent market position. |
| 4 | China | US$ XX.X Mn | XX.X% | As the largest and fastest-growing market, China benefits from a massive population, increasing healthcare expenditure, and strong government support for domestic medical device innovation. High prevalence of infectious diseases and expanding healthcare access drive demand for POC testing. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is undergoing massive healthcare transformation under Vision 2030, with substantial government investment in infrastructure and diagnostic capabilities. This drives a growing demand for advanced medical technologies, including POC solutions. |
Countries Covered (26)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, India, Japan, South Korea, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, South Africa, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | bioMérieux | XX.X% | Focus on integrated diagnostic solutions across infectious diseases and critical care, leveraging automation and multiplex PCR. | — | — | BIOFIRE FilmArrayVITEKBacT/ALERT+1 |
| 2 | QuidelOrtho | XX.X% | Deliver a broad portfolio of diagnostic solutions, from rapid point-of-care to high-throughput lab systems, covering infectious disease and immunoassay. | — | — | SavannaSofiaQuickVue+1 |
| 3 | QIAGEN | XX.X% | Provide sample to insight solutions, focusing on molecular testing and bioinformatics for research and clinical applications. | — | — | QIAstat-DxQIAcuityQIAgen EZ1+1 |
| 4 | DiaSorin | XX.X% | Specialize in immunodiagnostics and molecular diagnostics with a focus on high-growth specialties like infectious diseases and endocrinology. | — | — | LIAISON XLLIAISON MDXSimplexa+1 |
| 5 | SD Biosensor | XX.X% | Expand global reach with affordable and accessible diagnostic solutions, particularly for infectious diseases, leveraging rapid test and molecular platforms. | — | — | STANDARD M10STANDARD FSTANDARD Q+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
bioMérieux, QuidelOrtho, QIAGEN, DiaSorin, SD Biosensor, Seegene, Molbio Diagnostics, Revvity, OraSure Technologies, Biocartis, bioGX, Eiken Chemical, Co-Diagnostics, Novacyt, Accelerate Diagnostics, QuantuMDx, Vela Diagnostics, Biomeme, GeneReach Biotechnology, Fluxergy
The global Point-of-Care Molecular Testing market features a competitive landscape led by bioMérieux, QuidelOrtho, QIAGEN, DiaSorin, SD Biosensor, and Seegene, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
bioMérieux
QuidelOrtho
QIAGEN
DiaSorin
SD Biosensor
Seegene
Molbio Diagnostics
Revvity
OraSure Technologies
Biocartis
bioGX
Eiken Chemical
Co-Diagnostics
Novacyt
Accelerate Diagnostics
QuantuMDx
Vela Diagnostics
Biomeme
GeneReach Biotechnology
Fluxergy
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
BioDx Innovations Launches Next-Gen Multiplex POC Respiratory Panel
BioDx Innovations unveiled its 'RespiScan Pro,' a rapid point-of-care molecular test capable of simultaneously detecting 15+ respiratory pathogens in under 30 minutes. This launch targets faster diagnosis and treatment decisions in urgent care and primary settings.
Global Diagnostics Giant Acquires CRISPR-Based POC Startup 'GenieDx'
MegaCorp Diagnostics announced the strategic acquisition of GenieDx, a pioneer in advanced CRISPR-based point-of-care molecular testing technology. This move significantly bolsters MegaCorp's portfolio in rapid infectious disease and genetic screening diagnostics.
RapidTest Corp. Partners with National Hospital Chain for POC Platform Deployment
RapidTest Corp. has forged a major partnership with United Health Systems to integrate its high-throughput point-of-care molecular diagnostic platforms across hundreds of urgent care centers and satellite clinics. The collaboration aims to expand access to rapid and accurate diagnostic testing nationwide.
AI-Driven POC Molecular Diagnostics Firm Secures US$ XX.X Series C Funding
InnovateDx, a company leveraging AI for next-generation point-of-care molecular diagnostics focusing on antimicrobial resistance, successfully closed a US$ XX.X Series C funding round. The investment will accelerate R&D, clinical trials, and market expansion for its novel platforms.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $3.4 Bn |
| Market Size (Forecast) | $7.0 Bn |
| CAGR | 7.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 26 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Point-of-Care Molecular Testing Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The Point-of-Care Molecular Testing market is estimated at $3.4 Bn in 2025. It is forecast to reach $7.0 Bn in 2035, reflecting significant expansion in decentralized diagnostics.
The Point-of-Care Molecular Testing market is forecast to grow at a CAGR of 7.5% between 2025 and 2035. This growth is driven by increasing demand for rapid diagnostics and expanding healthcare access.
The main segments include Type (Infectious Disease, Oncology), Product (POC Molecular Analyzers, Test Cartridges & Kits), Technology (PCR Based, Isothermal Nucleic Acid Amplification Based), End-User (Hospitals & Clinics, Physician Offices), Form (Benchtop, Portable), and Functionality (Qualitative Analysis, Quantitative Analysis).
Leading companies in this market include bioMérieux, QuidelOrtho, QIAGEN, DiaSorin, SD Biosensor, Seegene, Molbio Diagnostics, Revvity, OraSure Technologies, Biocartis, bioGX, and Eiken Chemical.
The report covers market size and growth forecasts, detailed segmentation by type, product, technology, end-user, form, and functionality. It also includes regional analysis across major geographies and profiles of leading companies in the Point-of-Care Molecular Testing market.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Point-of-Care Diagnostics Market
$45.0 Bn in 2025 · 7.0% CAGR
Advanced Molecular Diagnostics Market
$14.6 Bn in 2025 · 16.2% CAGR
Companion Testing Technologies Market
$684.1 Mn in 2025 · 9.5% CAGR
Digital Molecular Diagnostics Market
$6.1 Bn in 2025 · 12.0% CAGR
Advanced Wound Care Market
$13.9 Bn in 2025 · 5.8% CAGR
Wound Care Products Market
$22.1 Bn in 2025 · 4.9% CAGR
AI Diagnostics Market
$2.1 Bn in 2025 · 16.3% CAGR
AI Echocardiography Market
$300.0 Mn in 2025 · 20.3% CAGR